Indeed, it was shown that daily systemic administration of rIL-18 had antitumor effects, whereas once weekly or bi-weekly administration favored lung metastases of melanoma cells and induced a strong immunosuppressive environment [155], hinting that the levels of IL-18 are critical for its effect. This evidence concerns the gene IL18 and melanoma.